Brokerages Set Janux Therapeutics, Inc. (NASDAQ:JANX) PT at $66.44

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have earned an average rating of “Moderate Buy” from the ten research firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $66.44.

JANX has been the subject of several analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $100.00 target price on shares of Janux Therapeutics in a report on Thursday. HC Wainwright reiterated a “buy” rating and issued a $63.00 target price on shares of Janux Therapeutics in a report on Thursday. Stifel Nicolaus initiated coverage on shares of Janux Therapeutics in a report on Friday, September 6th. They issued a “buy” rating and a $70.00 target price for the company. Wedbush reiterated an “outperform” rating and issued a $74.00 target price on shares of Janux Therapeutics in a report on Thursday, August 8th. Finally, UBS Group assumed coverage on shares of Janux Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $69.00 target price for the company.

Janux Therapeutics Trading Down 1.2 %

JANX opened at $54.21 on Friday. The company’s fifty day moving average price is $48.69 and its two-hundred day moving average price is $46.30. Janux Therapeutics has a 1-year low of $5.65 and a 1-year high of $65.60. The company has a market cap of $2.83 billion, a price-to-earnings ratio of -46.33 and a beta of 3.52.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 8.78% and a negative net margin of 291.17%. The business had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.50 million. The business’s revenue for the quarter was down 82.6% compared to the same quarter last year. As a group, equities analysts forecast that Janux Therapeutics will post -1.18 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Janux Therapeutics news, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of the stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $42.00, for a total transaction of $4,551,330.00. Following the completion of the transaction, the insider now owns 3,162,851 shares in the company, valued at $132,839,742. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $42.00, for a total value of $4,551,330.00. Following the completion of the transaction, the insider now directly owns 3,162,851 shares in the company, valued at approximately $132,839,742. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Andrew Hollman Meyer sold 50,000 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The shares were sold at an average price of $45.96, for a total transaction of $2,298,000.00. Following the completion of the transaction, the insider now owns 67,592 shares of the company’s stock, valued at $3,106,528.32. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 420,610 shares of company stock worth $19,288,666 over the last quarter. 29.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Janux Therapeutics

A number of large investors have recently modified their holdings of JANX. Capstone Investment Advisors LLC purchased a new stake in Janux Therapeutics in the first quarter valued at approximately $1,969,000. Janus Henderson Group PLC raised its stake in Janux Therapeutics by 1.8% in the first quarter. Janus Henderson Group PLC now owns 1,965,546 shares of the company’s stock valued at $73,961,000 after purchasing an additional 34,069 shares in the last quarter. Price T Rowe Associates Inc. MD purchased a new stake in Janux Therapeutics in the first quarter valued at approximately $739,000. Virtu Financial LLC purchased a new stake in Janux Therapeutics in the first quarter valued at approximately $609,000. Finally, Vanguard Group Inc. raised its stake in Janux Therapeutics by 38.6% in the first quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock valued at $51,127,000 after purchasing an additional 378,477 shares in the last quarter. 75.39% of the stock is currently owned by institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.